🎉 M&A multiples are live!
Check it out!

Organogenesis Valuation Multiples

Discover revenue and EBITDA valuation multiples for Organogenesis and similar public comparables like Mesoblast, Cynata Therapeutics, and Aroa Biosurgery.

Organogenesis Overview

About Organogenesis

Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.


Founded

2018

HQ

United States of America
Employees

869

Financials

LTM Revenue $484M

LTM EBITDA $48.3M

EV

$579M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Organogenesis Financials

Organogenesis has a last 12-month revenue of $484M and a last 12-month EBITDA of $48.3M.

In the most recent fiscal year, Organogenesis achieved revenue of $482M and an EBITDA of $15.8M.

Organogenesis expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Organogenesis valuation multiples based on analyst estimates

Organogenesis P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $433M $482M XXX XXX XXX
Gross Profit $346M $327M XXX XXX XXX
Gross Margin 80% 68% XXX XXX XXX
EBITDA $36.0M $15.8M XXX XXX XXX
EBITDA Margin 8% 3% XXX XXX XXX
Net Profit $15.5M $4.9M XXX XXX XXX
Net Margin 4% 1% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Organogenesis Stock Performance

As of April 15, 2025, Organogenesis's stock price is $4.

Organogenesis has current market cap of $549M, and EV of $579M.

See Organogenesis trading valuation data

Organogenesis Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$579M $549M XXX XXX XXX XXX $0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Organogenesis Valuation Multiples

As of April 15, 2025, Organogenesis has market cap of $549M and EV of $579M.

Organogenesis's trades at 1.2x LTM EV/Revenue multiple, and 12.0x LTM EBITDA.

Analysts estimate Organogenesis's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Organogenesis and 10K+ public comps

Organogenesis Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $579M XXX XXX XXX
EV/Revenue 1.2x XXX XXX XXX
EV/EBITDA 36.8x XXX XXX XXX
P/E 637.8x XXX XXX XXX
P/E/Growth 1.5x XXX XXX XXX
EV/FCF 138.7x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Organogenesis Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Organogenesis Valuation Multiples

Organogenesis's NTM/LTM revenue growth is 5%

Organogenesis's revenue per employee for the last fiscal year averaged $0.6M, while opex per employee averaged $0.4M for the same period.

Over next 12 months, Organogenesis's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Organogenesis's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Organogenesis and other 10K+ public comps

Organogenesis Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth 11% XXX XXX XXX XXX
EBITDA Margin 3% XXX XXX XXX XXX
EBITDA Growth -56% XXX XXX XXX XXX
Rule of 40 (SaaS-only) 8% XXX XXX XXX XXX
Revenue per Employee $0.6M XXX XXX XXX XXX
Opex per Employee $0.4M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue 10% XXX XXX XXX XXX
Opex to Revenue 72% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Organogenesis Public Comps

See public comps and valuation multiples for Regenerative Medicine and Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Lineage Cell Therapeutics XXX XXX XXX XXX XXX XXX
Arovella Therapeutics XXX XXX XXX XXX XXX XXX
Aroa Biosurgery XXX XXX XXX XXX XXX XXX
Cynata Therapeutics XXX XXX XXX XXX XXX XXX
Mesoblast XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Organogenesis M&A and Investment Activity

Organogenesis acquired  XXX companies to date.

Last acquisition by Organogenesis was  XXXXXXXX, XXXXX XXXXX XXXXXX . Organogenesis acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Organogenesis

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Organogenesis

When was Organogenesis founded? Organogenesis was founded in 2018.
Where is Organogenesis headquartered? Organogenesis is headquartered in United States of America.
How many employees does Organogenesis have? As of today, Organogenesis has 869 employees.
Who is the CEO of Organogenesis? Organogenesis's CEO is Mr. Gary S. Gillheeney, Sr.
Is Organogenesis publicy listed? Yes, Organogenesis is a public company listed on NAS.
What is the stock symbol of Organogenesis? Organogenesis trades under ORGO ticker.
When did Organogenesis go public? Organogenesis went public in 2016.
Who are competitors of Organogenesis? Similar companies to Organogenesis include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics.
What is the current market cap of Organogenesis? Organogenesis's current market cap is $549M
What is the current revenue of Organogenesis? Organogenesis's last 12-month revenue is $484M.
What is the current EBITDA of Organogenesis? Organogenesis's last 12-month EBITDA is $48.3M.
What is the current EV/Revenue multiple of Organogenesis? Current revenue multiple of Organogenesis is 1.2x.
What is the current EV/EBITDA multiple of Organogenesis? Current EBITDA multiple of Organogenesis is 12.0x.
What is the current revenue growth of Organogenesis? Organogenesis revenue growth between 2023 and 2024 was 11%.
Is Organogenesis profitable? Yes, Organogenesis is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.